Related references
Note: Only part of the references are listed.A Pharmacogenetics Service Experience for Pharmacy Students, Residents, and Fellows
Katarzyna Drozda et al.
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children
Atsushi Narita et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2013)
Gene sequencing leaves the laboratory
Erika Check Hayden
NATURE (2013)
University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.
Julie A. Johnson et al.
PHARMACOGENOMICS (2013)
Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review
Samantha Davies-Vorbrodt et al.
PHARMACOTHERAPY (2013)
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics
H. R. Ashbee et al.
BONE MARROW TRANSPLANTATION (2012)
A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine
Mirte M. Malingre et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control
Marin Kollef et al.
CLINICAL INFECTIOUS DISEASES (2012)
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Wan Beom Park et al.
CLINICAL INFECTIOUS DISEASES (2012)
Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time
David Andes et al.
CLINICAL INFECTIOUS DISEASES (2012)
Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2012)
Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics
P. H. O'Donnell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory
Charles M. Strom et al.
GENETICS IN MEDICINE (2012)
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
SeungHwan Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel
Emily S. Reese et al.
PHARMACOTHERAPY (2012)
The Development of Appropriate Dosage of Anti-bacterial and Anti-fungal Agents Based on Pharmacokinetics and Pharmacodynamics
Kazuaki Matsumoto
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2012)
Development and implementation of a pharmacist-managed clinical pharmacogenetics service
Kristine R. Crews et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
Peter F. Troke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
Maud Berge et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients
Si-Hyun Kim et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2011)
Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction
Brad Moriyama et al.
MYCOSES (2011)
Pharmacogenomics of the triazole antifungal agent voriconazole
Gerd Mikus et al.
PHARMACOGENOMICS (2011)
Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring
Arwa Hassan et al.
THERAPEUTIC DRUG MONITORING (2011)
Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients
Claudia Michael et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
How Many Steps along the Path Is Too Far?
G. L. Drusano
CLINICAL INFECTIOUS DISEASES (2010)
Voriconazole Pharmacokinetics and Pharmacodynamics in Children
Michael Neely et al.
CLINICAL INFECTIOUS DISEASES (2010)
Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
Hui-Yan Shi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers
He-Ping Lei et al.
ANNALS OF PHARMACOTHERAPY (2009)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
Kazuaki Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
Koki Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
Katsuyoshi Sugimoto et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
What is the Therapeutic Range for voriconazole?
Russell E. Lewis
CLINICAL INFECTIOUS DISEASES (2008)
Pharmacogenetics: From bench to byte
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Shu-Feng Zhou et al.
CURRENT DRUG METABOLISM (2008)
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
Mark-David Levin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
Norie Murayama et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Potent cytochrome P4502C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
Gerd Mikus et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
Kevin W. Garey et al.
CLINICAL INFECTIOUS DISEASES (2006)
Voriconazole therapeutic drug monitoring
J Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
K Tan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
Marcus J. P. Geist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
M Morrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics
J Rengelshausen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
S Trifilio et al.
BONE MARROW TRANSPLANTATION (2005)
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
M Ingelman-Sundberg
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
Y Ikeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Voriconazole: A new triazole antifungal agent
MM Pearson et al.
ANNALS OF PHARMACOTHERAPY (2003)
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
L Purkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal prophylaxis for severely neutropenic chemotherapy recipients -: A meta-analysis of randomized-controlled clinical trials
EJ Bow et al.
CANCER (2002)
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
TJ Walsh et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
